anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The mode selected for mechanical ventilation is settled by randomization either PRVC or VCV during radical cystectomy, then the mode of ventilation will be switched to the other mode during urinary diversion till the end of surgery according to the randomization sequence. The tidal volume in both groups will be set to deliver 6-8 mL/kg of ideal body weight. The respiratory rate (RR) will be adjusted to maintain an end tidal CO2 (ETCO2) level of 30-35 mmHg, the inspiratory to expiratory time (I: E) ratio will be1:2 and PEEP 5-8 cmH2O.
The invention provides a pharmaceutical composition for treating chronic hepatitis and liver cirrhosis. The composition is composed of or is prepared from radix aconiti lateralis preparata and pharmaceutic adjuvants. Furthermore, the radix aconiti lateralis preparata refers to a product obtained by performing heating treatment on the medicinal material radix aconiti lateralis preparata, and the heating treatment method comprises any one of decocting with water, steaming, frying and stewing. The invention also provides an application of the pharmaceutical composition for preparing medicines for treating the chronic hepatitis and liver cirrhosis. The clinical experiment proves that the effective rate of the pharmaceutical composition for treating chronic hepatitis is 90 percent, the effective rate for treating liver cirrhosis is 93.33 percent, and the symptoms can be improved after the pharmaceutical composition is taken by the patients for four weeks. The pharmaceutical composition disclosed by the invention is simple in medicinal composition and excellent in curative effect and does not have toxic or side effect.
Cardiovascular disease is the leading cause of death in the United States. Interpreting the relative danger of a lesion within the vasculature is limited by a lack of information on the composition of lesion. It is believed that a lesion which is high in lipids is more prone to rupture followed by thrombosis than a stable highly calcific, fibrotic, high grade stenosis. To address this recent hypothesis, a method of diagnosing and treating the most problematic vascular lesions is presented. The method employs the selective uptake of a lipophilic fluorescent compound by a lesion followed by the application of excitation light to the fluorescent compound-ladened lesion causing the fluorescent compound to emit fluorescence light. The intensity of the fluorescence light indicates the lipid content and/or the fibrous cap thickness, thus providing information on the potential danger of the lesion and enabling the clinician to treat the lesion in a manner which provides the patient with the best chance for clinical success.
INTRODUCTION: Human immunodeficiency virus (HIV) is no longer considered a contraindication for kidney transplantation (KT). KT management in HIV patients is a complex process with challenges, such as drug interactions between immunosuppression and antiretroviral (ARV) therapy. In our country, no KT has been performed thus far in this category of patients.
CASE PRESENTATION: We present the case of a 29-year-old female patient with HIV and end-stage renal disease (ESRD) who performed a KT from a related living donor in March 2022. KT immediate evolution was favorable. No transplant-related complications were reported. HIV viral load remained undetectable and CD4+ T cells were constantly > 500 cell/ μL, during the 18 months of follow-up. The main challenge in our case was the drug interaction between the protease inhibitor-based regimen and tacrolimus. This led to tacrolimus overdose, and, subsequently, change in ARV therapy. ARV switching was performed on a regimen based on integrase inhibitor and nucleoside reverse transcriptase inhibitors. After the ARV change, the therapeutic level of tacrolimus was easily reached and maintained. Kidney graft function remained normal during follow-up, despite tacrolimus overexposure, and no rejection or anti-HLA antibodies were observed. Another challenge was related to the donor's hepatitis C virus status (positive antibodies, negative nucleic acid test). The recipient did not develop seroconversion or detectable viremia at 3-, 6-, 12- and 18-months post-KT.
CONCLUSION: We reported the first case of a successful KT in an ESRD patient with HIV in Romania, in whom the post-transplant evolution was favorable.
Bortezomib 1.3 milligram (mg) per meter\^2 (m\^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
Carbon ion radiotherapy (CIRT) for pediatric cancer is currently limited because of the unknown risk of induction of secondary cancers. Medulloblastoma of Ptch1+/- mice offers a unique experimental system for radiation-induced carcinogenesis, in which tumors are classified into spontaneous and radiation-induced subtypes based on their features of loss of heterozygosity (LOH) that affect the wild-type Ptch1 allele. The present study aims to investigate in young Ptch1+/- mice the carcinogenic effect, and its age dependence, of the low-linear energy transfer (LET, ∼13 keV/µm) carbon ions, to which normal tissues in front of the tumor are exposed during therapy. We irradiated Ptch1+/- mice at postnatal day (P) 1, 4, or 10 with 290 MeV/u carbon ions (0.05-0.5 Gy; LET, 13 keV/µm) and monitored them for medulloblastoma development. Loss of heterozygosity of seven genetic markers on chromosome 13 (where Ptch1 resides) was studied to classify the tumors. Carbon ion exposure induced medulloblastoma most effectively at P1. The LOH patterns of tumors were either telomeric or interstitial, the latter occurring almost exclusively in the irradiated groups, allowing the use of interstitial LOH as a biomarker of radiation-induced tumors. Radiation-induced tumors developed during a narrow age window (most strongly at P1 and only moderately at P4, with suppressed tumorigenesis at P10). Calculated using previous results using 137Cs gamma rays, the values for relative biological effectiveness (RBE) regarding radiation-induced tumors were 4.1 (3.4, 4.8) and 4.3 (3.3, 5.2) (mean and 95% confidence interval) for exposure at P1 and 4, respectively. Thus, the RBE of carbon ions for medulloblastoma induction in Ptch1+/- mice was higher than the generally recognized RBE of 1-2 for cell killing, chromosome aberrations, and skin reactions.
Oral care compositions comprising: a) an oral care active; and b) an acrylic film forming polymer. In various embodiments, such polymers comprise monomeric units such as acrylic acid, methacrylic acid, acrylates, and combinations thereof. In one embodiment, the film forming polymer comprises a copolymer of a first monomeric unit selected from the group consisting of acrylic acid, methacrylic acid, and combinations thereof, with a second monomeric unit selected from the group consisting of acrylates, acrylamindes, acetates, and combinations thereof. In various embodiments, the polymer is a terpolymer comprising a combination of the second monomeric units. Preferably, the composition additionally comprises a lower alcohol, such as ethanol. In various embodiments, the oral care active comprises a whitening material, such as a peroxide.
PURPOSE:To provide the titled substance consisting of edible fibers composed mainly of cellulose and hemicellulose produced by removing starches, proteins, etc., from shell of grains or beans. CONSTITUTION:Shells of grains or beans (e.g. corn, rice bran, wheat bran, barley bran, soybean, adzuki bean, peas, etc.) is subjected e.g. to enzymatic treatment (e.g. with a starch-decomposition enzyme such as alpha-amylase, a protein- decomposition enzyme such as protease, etc.) to remove starches, proteins and, if necessary, lipids, inorganic materials, etc., to obtain edible fibers (having an NDF value of >=50%) composed mainly of cellulose and hemicellulose. The objective hepatic function-activation substance can be produced by using the edible fiber as a component. The substance is expected to have a remedying or preventive effect against various hepatic diseases and a normalizing action to hepatic function. It is absolutely free from toxicity and side effect. It can be produced at a low cost because of remarkably simplified production process.
PURPOSE: Anxiety is a mental state characterized by an intense sense of tension, worry, or apprehension relative to something adverse that might happen in the future. Anxiety is a known comorbidity in cough patients, yet its prevalence among those with chronic refractory cough (CRC) is unknown. Anxiety is not typically assessed during evaluation for CRC, but treatments for CRC such as neuromodulators and behavioral cough suppression therapy (BCST) may potentially attenuate anxiety. This preliminary study investigates the potential prevalence of anxiety in CRC and its possible role in treatment outcomes.
METHOD: CRC patients seen in a specialty clinic at the University of Utah or the University of Montana completed the Leicester Cough Questionnaire (LCQ) pre- and post-BCST treatment. Participants were dichotomized into positive anxiety screen (PAS) and negative anxiety screen (NAS) groups based on presence or absence of documented anxiety within electronic medical records at the University of Utah and based on a Generalized Anxiety Disorder-7 score > 5 at the University of Montana.
RESULTS: Of the 86 total participants, 37 (43%) were in the PAS group (29 females, Mage = 56 ± 13) and 49 (57%) were in the NAS group (36 females, Mage = 64 ± 14). Eighty-nine percent of CRC participants with a PAS reported a clinically meaningful improvement in LCQ total score following treatment compared to 65% of NAS participants. Furthermore, mean pre- to posttreatment change scores on the LCQ were significantly greater within the PAS group (p = .002, Cohen's d = 0.7, indicating a moderate to large effect size).
CONCLUSION: This preliminary study suggests that (a) anxiety may be prevalent among those with CRC and (b) those patients who screen positive for anxiety report greater benefit from BCST.
Improved fluid for intraocular infusion and irrigation and methods of preparation and use. The fluid is an aqueous physiologic saline solution containing from 2-15% by weight of an artificial, substantially non-antigenic oncotic agent of a colloid type, such as dextran having an average molecular weight in the range of from about 1,000 to 40,000. The solution also contains NaCl, CaCl2, dextrose and sodium bicarbonate, and is adjusted to have an osmolarity in the range of 260-400 mOsm/L and a pH in the range of from about 7 to 7.8. The solution may be used as a replacement fluid for the aqueous or vitreous humor, for the reestablishment of intraocular pressure during or after surgery, as an irrigating fluid during phacoemulsification, and generally for external eye surface rinsing during cataract surgery. The solution results in improved lens maintenance and corneal endothelial function during procedures such as vitrectomy, irrigation and aspiration of cataracts, and in phacoemulsification. Improvement is demonstrated, for example, by reduced corneal endothelial decompensation (inhibition of osmotic corneal swelling), by reduced water and sodium gain, by reduced potassium loss, and by recovery of the lens' ability to reverse electrolyte imbalances due to stress of the type typical of surgery, diabetes, ageing, and physical, chemical or biochemical trauma.
A total of 160 patients with histologically proven oropharyngeal SCC subjected to chemoradiation will be enrolled. Exclusion criteria include previous head or neck malignant tumor, a second malignant tumor, distant metastasis, contraindications to MRI (renal insufficiency, cochlear implant, cardiac pacemaker placement or intracranial aneurysmal ferromagnetic clips), and serum glucose level \>200 mg/dl. Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test.
BACKGROUND: Chronic intestinal failure (CIF) is a heterogeneous disease that affects pediatric and adult populations worldwide and requires complex multidisciplinary management. In recent years, many advances in intravenous supplementation support, surgical techniques, pharmacological management, and intestinal transplants have been published. Based on these advances, international societies have published multiple recommendations and guidelines for the management of these patients. The purpose of this paper is to show the differences that currently exist between the recommendations (ideal life) and the experiences published by different programs around the world.
METHODS: A review of the literature in PubMed from 1980 to 2024 was carried out using the following terms: intestinal failure, CIF, home parenteral nutrition, short bowel syndrome, chronic intestinal pseudo-obstruction, intestinal transplant, enterohormones, and glucagon-like peptide-2.
CONCLUSIONS: There is a difference between what is recommended in the guidelines and consensus and what is applied in real life. Most of the world's countries are not able to offer all of the steps needed to treat this pathology. The development of cooperative networks between countries is necessary to ensure access to comprehensive treatment for most patients on all continents, but especially in low-income countries.
The invention relates to the use of the compound biperiden as a MALT1 inhibitor in the treatment of a cancer disease. The invention relates in particular to a combination of biperiden and a phenothiazine for use in the treatment of a cancer disease. In a further aspect, the invention relates to a pharmaceutical composition for treating a cancer disease, which comprises biperiden as a MALT1 inhibitor. The invention further relates to a pharmaceutical composition comprising biperiden and at least one phenothiazine. In a further aspect, the invention relates to the use of biperiden in the treatment of a cancer disease. Furthermore, the invention provides a kit, which comprises a container that contains biperiden and at least one container that contains a phenothiazine compound.
PURPOSE OF REVIEW: Currently available evidence supporting the use of supplemental oxygen therapy (SOT) in chronic obstructive pulmonary disease (COPD) is complex, and data on the mortality reduction associated with SOT usage in patients with severe daytime resting hypoxemia have not been updated since the development of other treatments.
RECENT FINDINGS: No reduction in mortality was found when SOT was used in patients with moderate resting daytime, isolated nocturnal, or exercise-induced hypoxemia. However, some of these patients obtain other significant benefits during SOT, including increased exercise endurance, and a mortality reduction is possible in these 'responders'. The adverse effects of long-term oxygen therapy also need to be considered, such as reduced mobility and social stigma. Furthermore, conservative SOT could improve outcomes in the setting of COPD exacerbations compared with higher concentration oxygen regimens. Compared with usual fixed-dose SOT, automated oxygen administration devices might reduce dyspnea during exercise and COPD exacerbations.
SUMMARY: Current recommendations for SOT need to be revised to focus on patients who respond best and benefit most from this therapy. A conservative approach to SOT can reduce side effects compared with higher concentration oxygen regimens, and automated oxygen administration devices may help to optimize SOT.
ECMO early rehabilitation is led by a senior physiotherapist who has specialised training in ECMO care and coordinates individualised early physical training from randomisation to day 28 in ICU and liaises with the patient through to hospital discharge. The early rehabilitation intervention involves physical activity, functional retraining, strengthening exercises and mobilisation based on a reproducible, physiological approach.
Subjects will receive one treatment session of conventional cryolipolisys. Subcutaneous fat tissue will be cooled with the cryolipolitic device for 60 minutes. The treatmente area will be the abdomen and/or flanks according to each patient's needs (pragmatic treatment).
PURPOSE:To obtain an artificial denture cleaning agent having excellent denture plaque removing power and containing a plaque-decomposition enzyme formed by using glycerol, maltitol, xylitol, propylene glycol, etc., an active oxygen generation substance, a condensed phosphoric acid salt, etc. CONSTITUTION:This cleaning agent for artificial denture having excellent denture plaque removing power can be produced by compounding (A) a plaque- decomposition enzyme (e.g. dextranase) formed by using one or more excipients such as glycerol, maltitol, xylitol and propylene glycol, (B) an active oxygen generation substance (e.g. hydrogen potassium monopersulfate) and (C) a condensed phosphoric acid salt (e.g. sodium pyrophosphate) and/or anhydrous sodium sulfate and, as necessary, adding (D) an agent to promote the dissolution and dispersion of the cleaning agent and composed of a carbonate (e.g. sodium carbonate) and an acid (e.g. citric acid anhydride) a surfactant (e.g. sodium laurylsulfate) to improve the cleaning power, etc., to the composition.
The investigation assessed the clinical effect of a mouthrinse containing chlorhexidine (CHX) and sodium fluoride (NaF) during a 4-day period of non-brushing and a 6-week period of brushing. Two studies were designed as double-blind, randomized, cross-over clinical trials. In study I, 16 healthy subjects rinsed twice daily for 1 min during 4 days of no tooth brushing with four mouthrinse solutions: 1) 0.12% CHX + 0.2% NaF, 2) 0.2% NaF, 3) 0.12% CHX, and 4) placebo. In study 2, 16 healthy subjects rinsed with the same four solutions twice daily after tooth brushing during a 6-week period. Primary outcomes were plaque formation and gingivitis. Secondary outcomes were fluoride retention and microbiological parameters in plaque and saliva (total bacterial counts and mutans streptococci, lactobacilli and streptococci sanguinis counts). One way analyses of variance with post hoc Student-Newman-Keul´s statistical test was performed for comparisons between mouthrinses. Intragroup changes over time were analyzed with a paired t-test.
Chronic adipose tissue inflammation accompanied by macrophage accumulation and activation is implicated in the pathogenesis of insulin resistance and type 2 diabetes in humans. The transcriptional coregulator CREBZF is a key factor in hepatic metabolism, yet its role in modulating adipose tissue inflammation and type 2 diabetes remains elusive. The present study demonstrates that overnutrition-induced CREBZF links adipose tissue macrophage (ATM) proinflammatory activation to insulin resistance. CREBZF deficiency in macrophages, not in neutrophils, attenuates macrophage infiltration in adipose, proinflammatory activation, and hyperglycemia in diet-induced insulin-resistant mice. The coculture assays show that macrophage CREBZF deficiency improves insulin sensitivity in primary adipocytes and adipose tissue. Mechanistically, CREBZF competitively inhibits the binding of IκBα to p65, resulting in enhanced NF-κB activity. In addition, bromocriptine is identified as a small molecule inhibitor of CREBZF in macrophages, which suppresses the proinflammatory phenotype and improves metabolic dysfunction. Furthermore, CREBZF is highly expressed in ATM of obese humans and mice, which is positively correlated with proinflammatory genes and insulin resistance in humans. This study identifies a previously unknown role of CREBZF coupling ATM activation to systemic insulin resistance and type 2 diabetes.
Children often describe procedures involving needles as the most stressful portion of the hospital experience. 1,2 Many studies involving the perception of pain have highlighted the importance of attention for the perception of pain, and, conversely, the benefit of distraction for decreasing pain perception. 3,4 Virtual reality technologies (VR) have been shown to mitigate the experience of pain and anxiety in patients undergoing procedures in a number of different ways. 5,6 While small studies have demonstrated the use of VR to be effective in diminishing pain during intravenous (IV) placement for outpatient imaging in pediatric patients aged 8-12, there have not been large-scale studies assessing the use of VR during IV placement in the Pediatric Emergency Department. 7 Studies examining the use of VR during venipuncture and IV placement also frequently focus on self-reported or parent-reported pain, rather than objectively quantifying number of IV sticks and time to successful IV placement.8 Additionally, the pediatric age ranges which benefit from VR have not been well-established, with some studies citing benefits only in patients over 10 years of age, and others showing improvements in all age groups.7,9,10

This study aims to prospectively investigate the use of virtual reality headsets on the placement of IVs in a pediatric emergency department, by comparing the first stick success rate, total number of attempts, and the time to successful IV placement between patients who use virtual reality headset technology during the placement and those who receive the standard of care IV placement when child life ( individuals with special training in aiding and augmenting pediatric coping skills) is not available. The investigators will also compare the patient and parent perception of pain and anxiety associated with the IV placement in both study groups. Finally, by detailing which medications have been given prior to use of the VR for IV placement the investigators may evaluate for possible synergistic effects of VR with prior medication administration.
We will conduct a voluntary anonymous survey at four separate Sacramento area family planning clinics. We will introduce the research project to clinic staff, recruiting their support and participation, as they will be the main implementers. The survey will be offered to women in the waiting room before any pre-procedure counseling. We will include all women presenting to the clinic who are 18 years and older and planning to have a first trimester (\<12 weeks gestation) surgical abortion. Gestational age will be based on what the woman believes is her gestational age at presentation, before any evaluation in the clinic. Women who cannot understand or read the survey will be excluded. We hope to implement the survey at these two clinics for 3-4 months reaching a minimum of 200 women so as to obtain an adequate power for our study. The brief survey will include a cover letter explaining the study and stressing the anonymity and confidentiality. The surveys will include an envelope in which to place completed surveys; the envelope can be sealed by the participant and dropped in a collection bin. This process will allow the data to be collected anonymously. The survey data will then be synthesized first by descriptive analysis, followed by chi-square and multiple regression analyses. A statistician in the University of California Davis Department of Obstetrics and Gynecology will help when necessary.